Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 786 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated... September 20, 2021 Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... March 31, 2021 Load more HOT NEWS How to Improve Cancer-Related Fatigue Using Exercise: Expert Perspectives Immunotherapy for Breast Cancer Treatment: Is It an Option? Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With...
